Cooley LLP

We are only able to display limited information for this firm. We display more complete information for all of the following firms:

Cooley LLP has a strong track record advising global life sciences and healthcare companies, with many of the well-experienced team members leveraging advanced degrees in biology, pharmaceuticals and biotechnology. Key practice strengths include cross-border transactions, IPOs, M&A and licensing matters, as well as assisting investors and investment banks on strategic transactions. Shanghai-based Yiming Liu is well-regarded among leading healthcare founders, bankers and investors for his expertise in private financings, capital markets transactions, M&A and licensing matters. Patrick Loofbourrow splits his time between Singapore and Shanghai, reputed for his corporate practice, frequently acting for biotech and pharmaceutical companies on complex high-value transactions.
Legal 500 Editorial commentary

Testimonials

Collated independently by Legal 500 research team.

  • ‘The Cooley team has the broadest coverage in geographic practice and business functions, including financing, IP, human resources, benefits and deal transactions. ’

  • ‘Patrick Loofbourrow is outstanding. He's highly professional, responsive, approachable and very thorough. ’

Key clients

  • Akeso Inc.
  • Angitia

Work highlights

Advised FutureGen on its US$1.8 billion license agreement with AbbVie to develop FG-M701, a next-generation TL1A antibody for the treatment of IBD currently in preclinical development.